Notification That Quarterly Report Will Be Submitted Late (nt 10-q)
August 17 2020 - 4:03PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
(Check one):
|
¨ Form 10-K ¨ Form 20-F ¨ Form 11-K
x Form 10-Q
¨ Form
10-D ¨ Form N-SAR ¨ Form
N-CSR
|
|
|
|
For Period Ended: June 30, 2020
|
|
|
|
¨ Transition Report on Form 10-K
|
|
¨ Transition
Report on Form 20-F
|
|
¨ Transition Report on Form 11-K
|
|
¨ Transition Report on Form 10-Q
|
|
¨ Transition
Report on Form N-SAR
|
|
|
|
For the Transition Period Ended:
|
If the notification relates to a portion
of the filing checked above, identify the Item(s) to which the notification relates:
PART I — REGISTRANT INFORMATION
Timber Pharmaceuticals, Inc.
Full Name of Registrant
Not Applicable
Former Name if Applicable
50 Tice Blvd, Suite A26
Address of Principal Executive Office
(Street and Number)
Woodcliff Lake, NJ 07677
City, State and Zip Code
PART II — RULES 12b-25(b) AND (c)
If the subject report could not be filed
without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed.
(Check box if appropriate)
|
(a)
|
The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense
|
|
|
|
x
|
(b)
|
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
|
|
|
|
|
(c)
|
The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
|
PART III — NARRATIVE
State below in reasonable detail why Forms
10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed
time period.
Timber Pharmaceuticals, Inc. (the “Company”) was
unable to file its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2020 (the “Form 10-Q”) within
the prescribed time period on or before August 14, 2020 without unreasonable effort or expense. The Company requires additional
time to complete the accounting and preparation of the disclosures associated with its recently completed merger and associated
financing transactions. The Company plans to file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 (the “Form
10-Q”) with the Securities and Exchange Commission (“SEC”) as soon as practicable and within the five calendar
day period provided by Rule 12b-25 for delayed filings.
PART IV — OTHER INFORMATION
(1)
|
Name and telephone number of person to contact in regard to this notification:
|
|
|
|
Joseph Lucchese
|
|
(973)
|
|
314-9570
|
|
(Name)
|
|
(Area Code)
|
|
(Telephone Number)
|
|
|
(2)
|
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). [X] Yes [ ] No
|
|
|
(3)
|
Is it anticipated
that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected
by the earnings statements to be included in the subject report or portion thereof? x
Yes ¨ No
|
If so, attach an explanation of the anticipated
change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot
be made.
When filed, the Form 10-Q will reflect
the results of continuing operations of the Company as a result of the recently completed merger and financing transactions, significantly
changing the Company’s results of operations versus the last fiscal quarter. When filed, the Form 10-Q will reflect total
revenue of approximately $27,000 for the six months ended June 30, 2020 compared to no revenue for the same period in 2019. Also,
the Form 10-Q will reflect comprehensive loss of $18.8 million for the six months ended June 30, 2020 compared to comprehensive
loss of $0.3 million for the same period in 2019.
Timber Pharmaceuticals, Inc.
(Name of Registrant as Specified in Charter)
has caused this notification to be signed
on its behalf by the undersigned hereunto duly authorized.
Date:
|
August 17, 2020
|
By:
|
/s/ Joseph Lucchese
|
|
|
|
Name:
|
Joseph Lucchese
|
|
|
Title:
|
Chief Financial Officer
|
Timber Pharmaceuticals (AMEX:TMBR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Timber Pharmaceuticals (AMEX:TMBR)
Historical Stock Chart
From Apr 2023 to Apr 2024